CardioDynamics nets OK for BioZ Dx features

Impedance cardiography (ICG) developer CardioDynamics of San Diego has received U.S. Food and Drug Administration (FDA) 510(k) marketing clearance for ICG clinical parameters and the electronic medical record (EMR) interface capability for its BioZ Dx system.

The ICG clinical parameters include total arterial compliance (TAC) and Q-C time interval (QC). TAC allows the assessment of peripheral artery elasticity, an early marker of peripheral artery and cardiovascular disease. QC is designed to enhance assessment of cardiac contractility.

The BioZ Dx was developed through a partnership with Philips Medical Systems of Andover, MA.

By staff writers
September 28, 2007

Related Reading

CardioDynamics moves closer to Vermed sale, August 16, 2007

CardioDynamics outlines Nasdaq compliance options, August 9, 2007

CardioDynamics boosts sales force, December 12, 2006

CardioDynamics shows Q1 sales slump, April 7, 2006

CardioDynamics makes management moves, December 12, 2005

Copyright © 2007

Page 1 of 603
Next Page